Genotype–Phenotype-Guided Personalization of Azathioprine Therapy in Autoimmune Hepatitis: Real World Data from Clinical Practice

Background/Objectives: Azathioprine (AZA) remains a key maintenance therapy in autoimmune hepatitis (AIH), but the role of pharmacogenetic testing and thiopurine metabolite monitoring in routine clinical practice is not fully established. We aimed to characterize thiopurine metabolite profiles according to biochemical response and TPMT genotype and to assess how therapeutic drug monitoring (TDM) informs treatment decisions in adults with AIH. Methods: We conducted a retrospective single-center observational study including adults with probable or definite AIH treated with AZA and with at least one erythrocyte 6-thioguanine nucleotide (6-TGN) and 6-methylmercaptopurine (6-MMP) measurement. Complete biochemical response (CBR) was defined as the normalization of transaminases and IgG. TPMT genotyping was performed according to local practice. Results: Among 112 patients (67% female; median age 55 years), TPMT genotype was available in 96, including seven (7.3%) TPMT*1/3A heterozygotes. Heterozygotes had higher 6-TGN concentrations and virtually undetectable 6-MMP despite lower AZA doses. The median 6-TGN was 386 pmol/8 × 108 RBC. AZA dose and TPMT*1/*3A genotype were independently associated with higher 6-TGN concentrations (β = +77 pmol/8 × 108 RBC per 0.5 mg/kg/day, p = 0.035; and β = +290 pmol/8 × 108 RBC, p = 0.004, respectively). Single-point 6-TGN concentrations were not associated with CBR. TDM was followed by treatment modification in 38 patients (34%), including dose adjustment, treatment switching, or the identification of non-adherence. No AZA-related myelotoxicity was identified. Conclusions: Single-point 6-TGN concentrations did not discriminate biochemical response, supporting interpretation in a clinical context rather than reliance on fixed thresholds. TDM provided clinically actionable information, while TPMT genotype identified a distinct metabolite profile associated with higher 6-TGN exposure at lower AZA doses. Together, these data support individualized interpretation of pharmacogenetic and metabolite information in AIH.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2026-11-16
DOI
https://doi.org/10.3390/ph19111821
Primary Topic
Liver Diseases and Immunity
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Genotype–Phenotype-Guided Personalization of Azathioprine Therapy in Autoimmune Hepatitis: Real World Data from Clinical Practice

Ignasi Olivas, Ana Pascual‐Dapena, Sergio Rodríguez‐Tajes, María‐Carlota Londoño et al.
Pharmaceuticals
Liver Diseases and Immunity
article

Genotype–Phenotype-Guided Personalization of Azathioprine Therapy in Autoimmune Hepatitis: Real World Data from Clinical Practice

Ignasi Olivas, Ana Pascual‐Dapena, Sergio Rodríguez‐Tajes, María‐Carlota Londoño, Pinelopi Arvaniti, Ana Lizana, Jaime I. Sainz de Medrano, Judit Julian, Helena Hernández-Évole, Mercè Brunet
article en

Abstract

Background/Objectives: Azathioprine (AZA) remains a key maintenance therapy in autoimmune hepatitis (AIH), but the role of pharmacogenetic testing and thiopurine metabolite monitoring in routine clinical practice is not fully established. We aimed to characterize thiopurine metabolite profiles according to biochemical response and TPMT genotype and to assess how therapeutic drug monitoring (TDM) informs treatment decisions in adults with AIH. Methods: We conducted a retrospective single-center observational study including adults with probable or definite AIH treated with AZA and with at least one erythrocyte 6-thioguanine nucleotide (6-TGN) and 6-methylmercaptopurine (6-MMP) measurement. Complete biochemical response (CBR) was defined as the normalization of transaminases and IgG. TPMT genotyping was performed according to local practice. Results: Among 112 patients (67% female; median age 55 years), TPMT genotype was available in 96, including seven (7.3%) TPMT*1/3A heterozygotes. Heterozygotes had higher 6-TGN concentrations and virtually undetectable 6-MMP despite lower AZA doses. The median 6-TGN was 386 pmol/8 × 108 RBC. AZA dose and TPMT*1/*3A genotype were independently associated with higher 6-TGN concentrations (β = +77 pmol/8 × 108 RBC per 0.5 mg/kg/day, p = 0.035; and β = +290 pmol/8 × 108 RBC, p = 0.004, respectively). Single-point 6-TGN concentrations were not associated with CBR. TDM was followed by treatment modification in 38 patients (34%), including dose adjustment, treatment switching, or the identification of non-adherence. No AZA-related myelotoxicity was identified. Conclusions: Single-point 6-TGN concentrations did not discriminate biochemical response, supporting interpretation in a clinical context rather than reliance on fixed thresholds. TDM provided clinically actionable information, while TPMT genotype identified a distinct metabolite profile associated with higher 6-TGN exposure at lower AZA doses. Together, these data support individualized interpretation of pharmacogenetic and metabolite information in AIH.

PharmaceuticalsVol. 19(11)
Hospital Clínic de Barcelona (ES), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES), ERN GUARD-Heart (NL), Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES), Fundació Clínic per a la Recerca Biomèdica (ES), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), ERN RARE-LIVER (DE), Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (ES), Universitat de Barcelona (ES)
Societat Catalana de Digestologia, Instituto de Salud Carlos III
Good health and well-being
Liver Diseases and Immunity
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon